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background
 
Most renal transplants fail because of chronic allograft nephropathy or because the re-
cipient dies, but no reliable factor predicting long-term outcome has been identified. We
tested whether a renal arterial resistance index of less than 80 was predictive of long-
term allograft survival.
 
methods
 
The renal segmental arterial resistance index (the percentage reduction of the end-dia-
stolic flow as compared with the systolic flow) was measured by Doppler ultrasonogra-
phy in 601 patients at least three months after transplantation between August 1997 and
November 1998. All patients were followed for three or more years. The combined end
point was a decrease of 50 percent or more in the creatinine clearance rate, allograft
failure (indicated by the need for dialysis), or death.
 
results
 
A total of 122 patients (20 percent) had a resistance index of 80 or higher. Eighty-four of
these patients (69 percent) had a decrease of 50 percent or more in creatinine clearance,
as compared with 56 of the 479 patients with a resistance index of less than 80 (12 per-
cent); 57 patients with a higher resistance index (47 percent) required dialysis, as com-
pared with 43 patients with a lower resistance index (9 percent); and 36 patients with a
higher resistance index (30 percent) died, as compared with 33 patients with a lower re-
sistance index (7 percent) (P<0.001 for all comparisons). A total of 107 patients with a
higher resistance index (88 percent) reached the combined end point, as compared with
83 of those with a lower resistance index (17 percent, P<0.001). The multivariate relative
risk of graft loss among patients with a higher resistance index was 9.1 (95 percent con-
fidence interval, 6.6 to 12.7). Proteinuria (protein excretion, 1 g per day or more), symp-
tomatic cytomegalovirus infection, and a creatinine clearance rate of less than 30 ml per
minute per 1.73 m
 
2
 
 of body-surface area after transplantation also increased the risk.
 
conclusions
 
A renal arterial resistance index of 80 or higher measured at least three months after
transplantation is associated with poor subsequent allograft performance and death.
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hronic allograft nephropathy
 
and death with a functioning allograft ac-
count for 80 percent of allograft failures.
 
1,2
 
No measure accurately identifies patients at high
risk for allograft loss. We recently found that a renal
arterial resistance index of 80 or higher predicts a
poor outcome of treatment after correction of renal-
artery stenosis
 
3
 
 and also predicts worsening renal
function or death in patients with renal diseases
other than renal-artery stenosis.
 
4,5
 
 These findings
prompted us to conduct a prospective study involv-
ing recipients of renal transplants. We investigated
the long-term outcome in transplant recipients in
whom the resistance index was measured at least
3 months after transplantation (median, 40 months;
range, 3 to 317). We chose this time point because
we wanted to ensure that recovery from any acute
renal failure had occurred and that possible con-
founding influences of any complications of surgery
were avoided. We also compared the predictive val-
ue of the resistance index with that of other factors
associated with renal allograft failure.
 
study design and study patients
 
The ethics committee of the University of Hannover
approved the study, and all patients gave written in-
formed consent. Between August 1997 and Novem-
ber 1998, color Doppler ultrasonography was per-
formed by a single investigator in 776 consecutive
recipients of a renal transplant who were being fol-
lowed in our outpatient clinic. A total of 175 of
these patients were excluded from the study because
they had undergone transplantation less than three
months previously or because they had factors
present on the day of ultrasonography that influ-
enced the resistance-index value. Such factors in-
cluded compression of the kidney by adjacent mass-
es, acute tubular necrosis, untreated renal-artery
stenosis resulting in a 50 percent reduction in the
luminal diameter, hydronephrosis of grade 2 or
worse, and acute rejection.
 
6-9
 
 The patients were pro-
spectively stratified into two groups according to the
resistance index for their transplant: those with an
index of 80 or higher and those with an index of less
than 80.
 
primary end point
 
The combined primary end point was a reduction
of 50 percent or more in the creatinine clearance
rate from the value measured at the time of ultraso-
nography, development of end-stage renal failure
requiring the reinstitution of dialysis, or death with
a functioning graft. The creatinine clearance rate (in
milliliters per minute per 1.73 m
 
2
 
 of body-surface
area) and the rate of urinary protein excretion were
measured during the 24 hours preceding the ultra-
sonographic examination and at yearly intervals
thereafter. Urine collections were judged complete
on the basis of quantification of the total creatinine
excretion, corrected for age and sex. If the total cre-
atinine excretion was 25 percent or more below the
expected value (as it was for 91 of 601 patients), the
creatinine clearance rate was estimated according
to the Gault–Cockroft formula.
 
10
 
 Dialysis status and
vital status were ascertained from the patients or
their relatives. The mean (
 
±
 
SD) duration of follow-
up for patients with uncensored data (i.e., patients
who did not reach the combined end point) was
4.2
 
±
 
0.3 years (range, 3.3 to 4.9).
 
ultrasonographic determination
of the resistance index
 
Either an Ultramark 9 HDI ultrasound machine (Ad-
vanced Technology Laboratories) with a 2-to-4-MHz
curved-array multifrequency transducer with a 2.5-
MHz pulsed Doppler frequency or a Sienna Sono-
line ultrasound machine (Siemens) with a 3.5-MHz
convex-array transducer was used. The B-mode
measurements were performed at the same time as
the Doppler measurement of the resistance index.
The ultrasonographic procedure has been described
previously.
 
3,11
 
 Briefly, the maximal length, width,
and depth of the kidney were determined, and the
renal volume was calculated as one half the product
of the three dimensions. The renal parenchymal
width was measured from the capsule to the tip of a
renal pyramid.
Intrarenal Doppler signals were obtained from
two to three representative proximal segmental ar-
teries (the first vessels branching off the main renal
artery). The peak systolic velocity (V
 
max
 
) and the
minimal diastolic velocity (V
 
min
 
) were determined,
the renal segmental arterial resistance index was
calculated as 100¬[1 – (V
 
min
 
÷ V
 
max
 
)], and the re-
sults from the two or three measurements were
averaged. The reproducibility of resistance-index
measurements was tested in 12 renal-transplant
recipients by two independent investigators on two
consecutive days in order to calculate the intraob-
server, intrasession variability; the intraobserver,
intersession variability; and the interobserver, in-
trasession variability. The respective values for the
c
methods
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coefficient of variation were 2.2 percent, 4.8 per-
cent, and 3.7 percent. 
In order to rule out renal-artery stenosis in the
transplant, the course of the renal artery was deter-
mined with color-flow imaging. Stenosis was sus-
pected if a segment of the vessel showed color-flow
disturbance (“aliasing”). The maximal systolic-flow
velocity was measured at the site of aliasing (V
 
sten
 
)
and at the point most distal to the site (V
 
poststen
 
).
The area of stenosis (as a percentage of the total
area) was calculated according to the continuity
equation as 100¬[1 – (V
 
poststen
 
÷ V
 
sten
 
)]. With the
use of this approach, a stenosis resulting in a re-
duction in the area of 75 percent or more (equiva-
lent to a reduction in the diameter of 50 percent or
more) was diagnosed only when V
 
sten
 
 exceeded
V
 
poststen
 
 by a factor of four or more. The sensitivity,
specificity, and positive and negative predictive val-
ues of this method for detecting a reduction in the
diameter of 50 percent or more, when verified
against the findings on selective angiography in 70
renal-transplant recipients, were 100 percent, 88
percent, 96 percent, and 100 percent, respectively
(unpublished data).
 
biopsy substudy
 
In addition to performing this ultrasonographic
procedure in the 601 patients with long-term
follow-up, we also performed it in another 141 pa-
tients who, starting in December 2000, routinely
underwent biopsy six months after transplanta-
tion as part of a biopsy program designed to guide
routine clinical care. We compared their resistance-
index values with histologic findings suggestive
of chronic allograft nephropathy according to Banff
97 criteria.
 
12
 
 The presence or absence of tubular
atrophy, interstitial fibrosis, chronic allograft ne-
phropathy (i.e., the combination of tubular atro-
phy and interstitial fibrosis), and chronic allo-
graft arteriopathy (fibrous intimal thickening) was
noted, and the findings were graded from 0 to 3.
In addition, global glomerulosclerosis was evalu-
ated semiquantitatively (with 0 denoting no glo-
bally scarred glomeruli, 1 denoting less than 25 per-
cent globally scarred glomeruli, 2 denoting 25 to
50 percent, and 3 denoting more than 50 per-
cent). The same histologic criteria were applied to
a subgroup of the 601 patients for whom biopsy
was indicated because of worsening renal func-
tion or proteinuria at least one year after trans-
plantation (median, 5.2 years; range, 1.0 to 20.3).
In these patients, ultrasonography was performed
a median of 1.3 years before biopsy (range, 4.2
years before biopsy to 1.7 years after biopsy).
 
statistical analysis
 
The SPSS statistical package (version 11.0, SPSS)
and SAS software (version 8.2, SAS Institute) were
used for all statistical analyses. Unpaired t-tests, chi-
square analysis, or Kaplan–Meier analysis with the
log-rank test was used as appropriate to assess the
differences between groups. Cox proportional-haz-
ards analysis was used to calculate univariate and
multivariate hazard ratios as estimates of relative
risks. The number of years of follow-up was calcu-
lated from the date of ultrasonography until the date
of a first event or the last documented visit in our
outpatient clinic. For multivariate analysis, the effect
of multiple variables on worsening of renal func-
tion, need for dialysis, and death was evaluated in all
601 cases with stepwise forward Cox regression
analysis (with P=0.10 as the threshold level of sig-
nificance for the removal of the variable from analy-
sis and P=0.05 as the threshold for entry into the
model). 
The variables investigated were the resistance in-
dex; the number of renal transplantations; the cold-
ischemia time; the solution used for perfusion; the
presence or absence of cytomegalovirus viremia and
symptomatic infection; the age of the donor; the
number of mismatches at the HLA-A, B, and DR
loci; the number of acute interstitial and vascular re-
jections within and after the first three months after
renal transplantation; the occurrence or nonoccur-
rence of a delay in graft function of more than six
days after transplantation
 
13
 
; the percentage of
panel-reactive antibodies; whether the graft was
from a living or cadaveric donor; the type of under-
lying renal disease; the duration of dialysis; the sex
of the patient; whether transplantation occurred be-
fore or after the introduction of cyclosporine; the age
of the patient; the presence or absence of athero-
sclerosis in the heart, legs, or central nervous sys-
tem; the presence or absence of diabetes; the pres-
ence or absence of hypertension; the mean systolic
and diastolic blood pressure and pulse pressure
as measured at home; the degree of proteinuria;
the creatinine clearance rate; and the size, volume,
and parenchymal width of the transplanted kidney.
The pulse rate, the fasting serum glucose level, the
C-reactive protein level, cholesterol levels, the uric
acid level, height, and weight were always measured
on the day of the ultrasonographic investigation,
usually within two hours before ultrasonography,
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and information on concomitant drug use (angio-
tensin-converting–enzyme inhibitors, angiotensin-
receptor blockers, calcium-channel blockers, beta-
blockers, diuretics, alpha-blockers, moxonidine,
clonidine, other antihypertensive drugs, and sta-
tins) was always obtained on that day as well.
Extrapolations of median survival times were
performed with regression analysis (with SAS soft-
ware), with the assumption of a gamma distribu-
tion. All data are expressed as means 
 
±
 
SD unless
otherwise stated.
 
the resistance index as a predictor
 
Follow-up data were available for all 601 patients
(Table 1). Patients with resistance-index values of
80 or higher were significantly older, had had their
transplants for a longer time, had higher blood
pressure, had worse graft function, had more
severe proteinuria, and were more likely to have
coronary artery disease than patients with resist-
ance-index values below 80. However, only a re-
sistance-index value of 80 or higher accurately iden-
tified patients who subsequently had a decrease
of 50 percent or more in the creatinine clearance,
required dialysis, or died (sensitivity, 56 percent;
specificity, 96 percent).
A total of 122 patients (20 percent) had a resist-
ance index of 80 or higher. Eighty-four of these pa-
tients (69 percent) had a decrease of 50 percent or
more in the creatinine clearance rate, as compared
with 56 of the 479 patients with a resistance index
of less than 80 (12 percent); 57 patients with a high-
er resistance index (47 percent) required dialysis, as
compared with 43 patients with a lower resistance
index (9 percent); and 36 patients with a higher re-
sistance index (30 percent) died, as compared with
33 patients with a lower resistance index (7 percent)
(P<0.001 for all comparisons). A total of 107 pa-
tients with a higher resistance index (88 percent)
reached the combined end point, as compared with
83 of those with a lower resistance index (17 per-
cent; P<0.001). The resistance index was the strong-
est predictor of the combined end point (Table 2).
This finding was not altered when the variables
were considered as continuous rather than dichot-
omous variables or when patients were stratified
according to quintiles of age, time since transplan-
tation, creatinine clearance rate, or degree of pro-
teinuria (data not shown). The sensitivity of the re-
sistance index improved to 65 percent (73 of 113)
when the analysis included only the 113 patients
who had graft failure due to biopsy-proved chronic
allograft nephropathy (83 patients) or death from
cardiovascular causes (30). The other major causes
of a decrease of 50 percent or more in the creati-
nine clearance rate were recurrent disease (in 11
patients), rejection (in 7), and acute renal failure
(in 5). Six patients had allograft failure from other
results
 
* Plus–minus values are means ±SD. Clinical and laboratory data were obtained 
on the day of Doppler ultrasonography. Variables that did not differ signifi-
cantly between groups defined according to the resistance index were sex; 
number of transplantations; number of cytomegalovirus infections; the age of 
the donor; number of HLA mismatches (range, 0 to 6) for all patients and for 
patients who received cadaveric grafts; number of episodes of rejection; per-
centage of panel-reactive antibodies; duration of dialysis before transplanta-
tion; percentage of patients with hypertension; body weight; body-mass index; 
use or nonuse of angiotensin-converting–enzyme inhibitors, calcium-channel 
blockers, beta-blockers, clonidine, or other classes of antihypertensive drugs; 
length of the renal allograft; renal volume; and renal parenchymal width.
† A total of 98 patients with a resistance index of 80 or higher and 400 patients 
 
with a resistance index of less than 80 received cyclosporine.
 
Table 1. Demographic and Clinical Characteristics of the Patients and Their 
Allografts at Base Line.*
Characteristic Resistance Index P Value
 
≥80 
(N=122)
<80 
(N=479)
 
Patient-related factors
 
Age — yr 57±11 48±13 <0.001
Coronary artery disease — no. (%) 36 (30) 89 (19) 0.01
Diabetes — no. (%) 34 (28) 74 (15) 0.002
Systolic blood pressure — mm Hg 144±19 137±15 <0.001
Diastolic blood pressure — mm Hg 79±10 82±10 0.01
No. of classes of antihypertensive drugs 2.9±1.3 2.5±1.4 0.01
 
Graft-related factors
 
Cold-ischemia time — hr 25.0±6.7 23.2±8.4 0.03
Delayed graft function (>6 days) — no. (%) 40 (33) 94 (20) 0.002
Time since transplantation — yr 6.6±5.5 4.6±4.6 <0.001
Living kidney donor — no. (%) 2 (2) 41 (9) 0.005
Euro–Collins perfusion solution — no. (%) 49 (40) 108 (23) <0.001
Trough level of cyclosporine — ng/ml† 108±37 122±34 <0.001
 
Laboratory values
 
Creatinine clearance — ml/min/1.73 m
 
2
 
 
of body-surface area
51±29 65±28 <0.001
Proteinuria — g of protein excretion/day 1.1±1.8 0.5±1.0 <0.001
Serum C-reactive protein level >5 mg/liter 
— no. (%)
76 (62) 215 (45) 0.001
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known causes, and 19 had allograft failure from
unknown causes. Noncardiovascular causes of
death included infection (in 10 patients), cancer
(in 10), other known causes (in 6), and unknown
causes (in 13).
 
other possible predictors
 
Univariate analysis revealed a number of variables
that differed significantly between the patients who
reached the combined end point and those who did
not (Fig. 1). However, none of these variables had a
discriminatory power equal to that of the resist-
ance index, as evidenced by the lower relative risks
associated with these variables. Multivariate analy-
sis of the combined end point (Table 3) or the vari-
ous end points separately (Table 4) did not alter
these findings. Moxonidine treatment, although
used in only a small number of patients, was the
only factor that significantly reduced the risk of the
combined end point in the multivariate analysis
(Table 3).
 
prediction of death
 
Kaplan–Meier curves for the combined end point of
a reduction of 50 percent or more in the creatinine
clearance rate, the need for dialysis, or death and for
all end points considered separately (Fig. 2) were
calculated for the group with a resistance index of
80 or higher and the group with a resistance index
of less than 80. When patients who died were in-
cluded in the analysis, patients with a resistance in-
dex of 80 or higher had a median allograft survival
of 2.5 years (95 percent confidence interval, 2.3 to
2.6), as compared with 23.3 years (95 percent con-
fidence interval, 5.4 to 100.5) among patients with
a resistance index of less than 80.
 
verification of cutoff
 
In an analysis using a receiver-operating-character-
istic curve, we retrospectively evaluated the accuracy
of the predefined cutoff value for the resistance in-
dex. The highest sensitivity (56 percent) and speci-
ficity (96 percent) were attained at a resistance-index
value of 0.795, confirming the accuracy of the pre-
defined value of 0.80.
 
correlations with other measures
 
Among the 141 additional patients who underwent
biopsy at six months, tubular atrophy occurred more
frequently among patients with a resistance index
 
Table 2. Sensitivity, Specificity, and Positive and Negative Predictive Values of the Renal Resistance Index 
and Other Factors for the Prediction of the Combined End Point of a Decrease of at Least 50 Percent 
in the Creatinine Clearance Rate, the Need for Dialysis, or Death.
Analysis Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
 
percent (number/total number)
 
Resistance index ≥80
 
As predictor of the combined end point 56 (107/190) 96 (396/411) 88 (107/122) 83 (396/479)
As predictor of the need for dialysis 57 (57/100) 87 (436/501) 47 (57/122) 91 (436/479)
As predictor of death 52 (36/69) 84 (446/532) 30 (36/122) 93 (446/479)
As predictor of decrease of ≥50% in creatinine 
clearance
60 (84/140) 92 (423/461) 69 (84/122) 88 (423/479)
 
Other risk factors as predictors 
of the combined end point
 
Cold-ischemia time >12 hr 97 (184/190) 9 (38/411) 33 (184/557) 86 (38/44)
Urinary protein excretion ≥1 g/day 26 (49/190) 95 (390/411) 70 (49/70) 73 (390/531)
Creatinine clearance <30 ml/min/1.73 m
 
2
 
21 (39/190) 95 (392/411) 67 (39/58) 72 (392/543)
Donor age >65 yr 11 (20/190) 95 (390/411) 49 (20/41) 70 (390/560)
Renal parenchymal width <15 mm 15 (29/190) 96 (396/411) 66 (29/44) 71 (396/557)
Pulse pressure >70 mm Hg 32 (60/190) 86 (354/411) 51 (60/117) 73 (354/484)
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Figure 1. Univariate Relative Risk of a Decrease of 50 Percent or More in the Creatinine Clearance, the Need for Dialysis, or Death
after Doppler Ultrasonography Associated with Selected Variables.
 
Horizontal lines represent the 95 percent confidence intervals. To convert value for glucose to millimoles per liter, multiply by 0.05551. The 
body-mass index is the weight in kilograms divided by the square of the height in meters. To convert value for uric acid to micromoles per liter, 
multiply by 59.48. To convert value for cholesterol to millimoles per liter, multiply by 0.02586. HTK denotes histidine–tryptophan–ketoglut-
arate, UW University of Wisconsin, and ACE angiotensin-converting enzyme. The relative risks are shown on a logarithmic scale.
Resistance index ≥80
Urinary protein excretion >1 g/day
Creatinine clearance <30 ml/min/1.73 m2
Renal parenchymal width <15 mm
Cold-ischemia time >12 hr
Creatinine clearance <50 ml/min/1.73 m2
Cadaveric transplant
Euro–Collins perfusion solution (vs. HTK or UW solution)
Use of diuretic
Coronary heart disease
Pulse >80 beats/min
Pulse pressure >70 mm Hg
Systolic blood pressure >140 mm Hg
Trough level of cyclosporine <100 ng/ml
Graft function delayed >6 days
Time since transplantation >6 yr
Age >65 yr
Athero-occlusive disease of legs
Fasting serum glucose level >126 mg/dl
Symptomatic cytomegalovirus infection
Ischemic nephropathy as underlying disease
Donor age >65 yr
Serum C-reactive protein level >5 mg/liter
Rejection after 3 mo
≥2 Antihypertensive-drug classes
Cytotoxic antibodies >50%
Length of kidney <12 cm
Serum uric acid level >8 mg/dl
Use of statins
Dialysis >1 yr before transplantation
Use of ACE inhibitors
Body-mass index >30
Diabetes mellitus
Use of calcium-channel blockers
≥1 Episodes of rejection
≥4 HLA mismatches (with a cadaveric donor)
Serum cholesterol level >245 mg/dl
Female sex
Cytomegalovirus viremia after transplantation
Hypertension
Diastolic blood pressure >90 mm Hg
Use of moxonidine
≥1 Renal transplantations
Use of alpha-blockers
Relative Risk
0.1 10.0 15.01.0
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of 80 or higher than among those with a lower re-
sistance index (relative risk, 8.6; 95 percent confi-
dence interval, 1.1 to 67) but the semiquantitative
histologic scores were not correlated with the resist-
ance index. However, direct correlations were ob-
served between the resistance index and the degree
of interstitial fibrosis (R
 
2
 
=0.07), the degree of tu-
bular atrophy (R
 
2
 
=0.07), the degree of chronic
allograft nephropathy (R
 
2
 
=0.07), the degree of
chronic allograft arteriopathy (R
 
2
 
=0.11), and the
sum of the scores for chronic allograft nephropa-
thy and chronic allograft arteriopathy (R
 
2
 
=0.12)
among the 187 patients in the main study in whom
an indicated biopsy was performed at least one year
after transplantation (P<0.001 for all correlations).
No correlation was observed between the glomeru-
losclerosis score and the resistance index (R
 
2
 
=0.02,
P=0.08).
Among the 601 study patients, direct correla-
tions (P<0.001) were also observed between the re-
sistance index and the age of the recipient (R
 
2
 
=
0.20), the pulse pressure (R
 
2
 
=0.14), the systolic
blood pressure (R
 
2
 
=0.04), the degree of proteinuria
(R
 
2
 
=0.04), the base-line serum creatinine concen-
tration (R
 
2
 
=0.04), and the blood glucose concentra-
tion (R
 
2
 
=0.03). Inverse correlations were observed
between the resistance index and the diastolic blood
pressure (R
 
2
 
=0.04) and between the resistance
index and the creatinine clearance rate (R
 
2
 
=0.05).
These factors explained 34 percent of the variation
in the resistance index (R
 
2
 
=0.34).
We found that a resistance index of 80 or higher in
an allograft was a strong predictor of both allograft
failure and death with a functioning graft. Various
risk factors — including older age of the donor or
the recipient, poorer renal function at one year, the
presence of proteinuria, the presence and the degree
of hypertension, a greater number of HLA mis-
matches, delayed graft function, and longer time
since transplantation — have all been proposed as
means for differentiating between patients with a
good chance of long-term survival of a renal allo-
graft and those with a poor chance.
 
13-17
 
 These fac-
tors also came into play in our study. However, none
of them, alone or in combination,
 
18
 
 had a predictive
value approaching that of an increased resistance-
index value. 
Since the resistance index is significantly corre-
lated with many established cardiovascular risk fac-
tors, such as age, coronary heart disease, increased
systolic and pulse pressure, and decreased renal
function, it is not surprising that increased renal
vascular resistance predicts not only graft failure but
also death due to cardiovascular disease. Cardio-
vascular disease is the major cause of death in renal-
transplant recipients. Several authors have found
an increased resistance index particularly in pa-
tients who have signs of hypertensive end-organ
damage such as microalbuminuria, left ventricular
hypertrophy, increased carotid-wall thickness, and
overt carotid atherosclerosis.
 
19-21
 
 The resistance
index during long-term follow-up has been used
to diagnose allograft nephropathy.
 
6,22
 
 No close as-
sociation was observed between the resistance in-
dex and renal histology in these earlier studies or in
our investigation.
 
23
 
 Trillaud et al. did not find a
relation between the resistance index measured
6 days after renal transplantation and the level of re-
nal function at 12 months.
 
24
 
 However, these inves-
tigators did not use the resistance index to predict
allograft survival or death with a functioning graft.
The renal resistance index is nonspecific and is
influenced by many factors. Some are unrelated to
disease. For example, the site at which renal resist-
discussion
 
* The combined end point was a decrease of 50 percent or more in the creatinine 
 
clearance rate, the need for dialysis, or death. CI denotes confidence interval.
 
Table 3. Relative Risk of Allograft Loss among the 601 Patients, According to 
Selected Risk Factors.*
Risk Factor
No. of 
Patients
Relative Risk of the Combined
End Point (95% CI)
 
Univariate
Analysis
Multivariate
Analysis
Renal resistance index ≥80 122 10.4 (7.8–14.0) 9.1 (6.6–12.7)
Urinary protein excretion ≥1 g/day 70 4.7 (3.4–6.5) 4.3 (2.9–6.2)
Symptomatic cytomegalovirus 
infection
11 1.9 (0.8–4.6) 3.0 (1.2–7.3)
Creatinine clearance <30 ml/min/
1.73 m
 
2
 
58 3.9 (2.7–5.6) 2.4 (1.6–3.5)
Ischemic nephropathy as under-
lying disease
36 2.0 (1.2–3.3) 2.4 (1.4–4.1)
Donor age >65 yr 41 1.9 (1.2–3.0) 1.8 (1.1–3.0)
Euro–Collins perfusion solution 157 2.1 (1.6–2.9) 1.6 (1.2–2.2)
Pulse >80 beats per min 189 1.8 (1.3–2.4) 1.4 (1.0–1.9)
Coronary heart disease 125 1.8 (1.3–2.5) 1.4 (1.0–2.0)
Moxonidine use 33 0.8 (0.4–1.5) 0.3 (0.1–0.6)
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ance is measured
 
25
 
 and the increased intraabdom-
inal pressure during forced inspiration (the Valsalva
maneuver) influence the index.
 
26
 
 A pulse rate of
less than 50 beats per minute may increase the re-
sistance index, and a pulse rate of more than 70
beats per minute may lower it.
 
27
 
 Finally, increasing
age is also associated with an increased resistance
index, particularly in hypertensive patients.
 
28
 
 Two
common renal diseases that are associated with an
increased renal resistance index are diabetic and
hypertensive nephrosclerosis.
 
29
 
 Other diseases that
also increase the index are acute renal failure and
urinary tract obstruction with hydronephrosis. We
attempted to exclude all extrarenal variables. We
carefully excluded patients with potentially revers-
ible renal disease states such as urinary tract ob-
struction and acute rejection.
The resistance index was correlated not with the
histologic features of the allograft at six months, as
was seen in the 141 patients in the biopsy study but,
rather, with histologic findings obtained at least one
year after transplantation. However, the latter re-
sults are confounded by the fact that only 31 percent
of the 601 renal-transplant recipients underwent a
renal biopsy. Thus, we are not able to rule out sam-
pling errors entirely.
 
12
 
 Moreover, the resistance in-
dex was correlated more closely with characteristics
of the recipients, such as age and arterial pulse pres-
sure, suggesting that extrarenal factors have a major
effect on the resistance index in the allograft.
 
9,30
 
The factors influencing the resistance index ex-
plained only 34 percent of the variation we found
in the resistance index. Thus, there are other opera-
tive variables that we were unable to define.
We observed a possible favorable effect exerted
by moxonidine treatment for hypertension in cyclo-
sporine-treated patients. This observation may be
spurious, since the numbers were small. Neverthe-
less, cyclosporine has been shown to increase sym-
pathetic-nerve activity
 
31
 
 and to decrease brachial-
artery distensibility.
 
32
 
 Since an increased resistance
index was correlated most closely with the pulse
pressure, a crude marker of vascular stiffness, a sub-
stance such as moxonidine that inhibits sympathet-
ic-nerve activity could positively influence vascular
stiffness in renal-transplant recipients. Other drugs
that could be tested for their effect on the resistance
index are lisinopril,
 
33
 
 the prostacyclin analogue il-
oprost,
 
34
 
 and tacrolimus.
 
35
 
 The use of the Euro–
Collins solution for perfusion of the allograft has
been associated with higher resistance and poorer
outcomes than the University of Wisconsin solution
not only in our study, but also in another study.
 
36
 
Our study has several limitations. We did not per-
form renal histologic analyses in all 601 patients,
nor did we routinely perform parallel duplex ultra-
sonographic studies in these patients. However, our
more recent patients are undergoing repeated biop-
sies and parallel duplex ultrasonographic studies on
a regular basis. The histologic findings will have to
be graded quantitatively in order to permit better
correlation with the results on ultrasonography. The
data we obtained at six months from the biopsies
 
* To convert values for glucose to millimoles per liter, multiply by 0.05551.
 
Table 4. Relative Risk of a Decrease of 50 Percent or More in the Creatinine 
Clearance Rate, the Need for Dialysis, or Death, According to Selected 
Variables.
Variable Relative Risk (95% CI)
 
Univariate
Analysis
Multivariate
Analysis
 
Decrease of ≥50% in the creatinine 
clearance rate
 
Renal resistance index ≥80 12.1 (8.5–17.1) 12.2 (8.2–18.2)
Symptomatic cytomegalovirus infection 2.9 (0.9–9.7) 5.3 (2.1–13.0)
Urinary protein excretion ≥1 g/day 5.7 (4.0–8.3) 4.7 (3.1–7.1)
Ischemic nephropathy as underlying disease 2.3 (1.3–3.9) 3.5 (1.9–6.1)
Creatinine clearance <30 ml/min/1.73 m
 
2
 
4.4 (3.0–6.6) 2.6 (1.6–4.0)
Rejection after 3 mo 2.0 (0.7–5.7) 2.2 (1.3–3.9)
Pulse rate >80 beats per min 2.0 (1.4–2.7) 1.5 (1.1–2.2)
 
Need for dialysis
 
Renal resistance index ≥80 9.4 (6.2–14.0) 8.8 (5.5–14.1)
Symptomatic cytomegalovirus infection 3.4 (1.4–8.4) 6.9 (2.7–17.5)
Urinary protein excretion ≥1 g/day 6.8 (4.5–10.3) 5.3 (3.3–8.4)
Ischemic nephropathy as underlying disease 2.8 (1.6–5.1) 2.8 (1.5–5.2)
Creatinine clearance <30 ml/min/1.73 m
 
2
 
5.0 (3.2–7.8) 2.8 (1.7–4.6)
Rejection after 3 mo 1.9 (1.0–3.5) 2.6 (1.4–4.9)
Pulse rate >80 beats per min 2.0 (1.4–3.0) 2.2 (1.4–3.5)
 
Death
 
Renal resistance index ≥80 8.9 (5.5–14.4) 7.2 (4.3–12.0)
Coronary heart disease 3.1 (1.9–5.0) 3.0 (1.8–4.9)
Creatinine clearance <30 ml/min/1.73 m
 
2
 
2.9 (1.5–5.6) 2.5 (1.3–5.0)
Urinary protein excretion ≥1 g/day 2.3 (1.2–4.5) 2.5 (1.2–5.2)
Fasting serum glucose level >126 mg/dl* 2.8 (1.6–4.6) 2.2 (1.3–3.7)
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specified in the protocol probably did not represent
sufficiently long-term follow-up to permit a highly
sensitive comparison between histologic features
and the resistance index.
We suggest that a Doppler ultrasonographic
study performed three or more months after trans-
plantation can predict long-term allograft out-
comes. Our data also suggest that longitudinal
Doppler studies may be useful in monitoring inter-
ventions such as different immunosuppressive pro-
tocols or in comparing the capability of various anti-
hypertensive drugs to improve allograft outcomes.
Such studies may reduce the need for sequential re-
nal biopsies, with their associated risks. However,
an increased resistance index could mean acute vas-
cular rejection with endarteritis, chronic allograft
nephropathy, or both. Only a renal biopsy can dis-
tinguish among these conditions.
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Figure 2. Kaplan–Meier Analyses of Time to the Predefined Combined End Point and the Time to Each End Point Considered Separately.
 
The starting point was the time of ultrasonographic examination of the renal transplant. Values were calculated separately for the 479 patients 
with a resistance index of less than 80 and the 122 patients with a resistance index of 80 or higher.
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